DE69305313D1 - Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen - Google Patents

Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen

Info

Publication number
DE69305313D1
DE69305313D1 DE69305313T DE69305313T DE69305313D1 DE 69305313 D1 DE69305313 D1 DE 69305313D1 DE 69305313 T DE69305313 T DE 69305313T DE 69305313 T DE69305313 T DE 69305313T DE 69305313 D1 DE69305313 D1 DE 69305313D1
Authority
DE
Germany
Prior art keywords
protein
therapeutic protein
orally
oral administration
stabilizing agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69305313T
Other languages
English (en)
Other versions
DE69305313T3 (de
DE69305313T2 (de
Inventor
J Gabriel Michael
Allen Litwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25541237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69305313(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of DE69305313D1 publication Critical patent/DE69305313D1/de
Application granted granted Critical
Publication of DE69305313T2 publication Critical patent/DE69305313T2/de
Publication of DE69305313T3 publication Critical patent/DE69305313T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE1993605313 1992-12-22 1993-01-04 Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen Expired - Lifetime DE69305313T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99493292A 1992-12-22 1992-12-22

Publications (3)

Publication Number Publication Date
DE69305313D1 true DE69305313D1 (de) 1996-11-14
DE69305313T2 DE69305313T2 (de) 1997-02-20
DE69305313T3 DE69305313T3 (de) 2001-06-21

Family

ID=25541237

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1993605313 Expired - Lifetime DE69305313T3 (de) 1992-12-22 1993-01-04 Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen

Country Status (12)

Country Link
US (1) US5591433A (de)
EP (1) EP0603992B2 (de)
JP (1) JPH0710771A (de)
AT (1) ATE143803T1 (de)
AU (1) AU664222B2 (de)
CA (1) CA2086631C (de)
DE (1) DE69305313T3 (de)
DK (1) DK0603992T4 (de)
ES (1) ES2095001T5 (de)
GR (2) GR3022090T3 (de)
NZ (1) NZ245618A (de)
SG (1) SG52402A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2109362T3 (es) * 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
BR9507452A (pt) * 1994-04-08 1997-08-05 Brigham & Womens Hospital Composição farmacêutica uso de um polipeptídeo não-interferon uso de uma quantidade de um antígeno padronizado e uma quantidade de um polipeptídeo não-interferon e produto contendo (1) uma quantidade de um antígeno padronizado e (11) uma quantidade de um polipeptídeo não-interferon
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
WO1998007443A1 (fr) * 1996-08-20 1998-02-26 Freund Industrial Co., Ltd. Microspheres contenant des immunogenes, procede de fabrication et procede permettant d'immuniser des animaux a l'aide de ces microspheres
WO1998009645A1 (fr) * 1996-09-04 1998-03-12 Dott Research Laboratory Compositions medicamenteuses contenant des peptides, destinees a l'administration orale
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
CA2319437C (en) * 1998-01-31 2009-06-16 University Of Arkansas Methods and reagents for decreasing allergic reactions
US6328967B1 (en) * 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
PL193929B1 (pl) 1998-03-23 2007-04-30 Gen Mills Inc Jadalny produkt na bazie skrobi, kompozycja odżywcza oraz sposób wytwarzania jadalnego produktu
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
GB9818591D0 (en) * 1998-08-27 1998-10-21 Danbiosyst Uk Pharmaceutical composition
WO2000054797A2 (en) 1999-03-17 2000-09-21 Novartis Ag Pharmaceutical compositions comprising tgf-beta
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
US20010026800A1 (en) * 2000-01-07 2001-10-04 Michael Jacob G. Selective activation of a TH1 or TH2 lymphocyte regulated immune response
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
AU1951001A (en) * 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US6468568B1 (en) 2000-06-16 2002-10-22 General Mills, Inc. Oligosaccharide encapsulated mineral and vitamin ingredients
US6436453B1 (en) 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US6558718B1 (en) 2000-06-19 2003-05-06 General Mills, Inc. Nutrient clusters for food products and methods of preparation
CN1268641C (zh) 2000-11-10 2006-08-09 普罗蒂奥制药公司 载脂蛋白类似物
WO2002098422A1 (en) * 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
KR20040047915A (ko) * 2001-10-15 2004-06-05 룀 게엠베하 운트 콤파니 카게 활성제로서 펩타이드 또는 단백질을 함유하는 생약 형태를제조하기 위한 공중합체의 용도
KR100469943B1 (ko) * 2002-03-20 2005-02-02 삼성정밀화학 주식회사 장용성 코팅제로 사용되는 아크릴 공중합체의 제조 방법
US20040043070A1 (en) * 2002-05-14 2004-03-04 Ayres James W. Hot melt coating by direct blending and coated substrates
US7431986B2 (en) 2002-07-24 2008-10-07 General Mills, Inc. Encapsulation of sensitive components using pre-emulsification
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
EP1638607A1 (de) * 2003-04-08 2006-03-29 Progenics Pharmaceuticals, Inc. Kombinationstherapie gegen obstipation mit einem laxativ und einem peripheren opioid-antagonisten
PL2368553T3 (pl) * 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
US20070141071A1 (en) * 2003-05-14 2007-06-21 Oregon State University Hot melt coating by direct blending and coated substrates
US20060029590A1 (en) * 2004-06-10 2006-02-09 Christopher Thanos Administration of neutral endopeptidase to treat inflammatory bowel disease
JP2008502605A (ja) * 2004-06-16 2008-01-31 スマート ドラッグ システムズ インコーポレイティド 徐放性ワクチン組成物
EP1845989A1 (de) * 2005-01-20 2007-10-24 Progenics Pharmaceuticals, Inc. Verwendung von methylnaltrexon und damit zusammenhängenden verbindungen zur behandlung postoperativer gastrointestinaler dysfunktionen
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
CA2624503A1 (en) * 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
WO2007112747A1 (en) * 2006-03-31 2007-10-11 Curalogic A/S Immunogen combinations
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
AU2008233129B2 (en) * 2007-03-29 2014-03-20 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
ES2540551T3 (es) * 2007-03-29 2015-07-10 Wyeth Llc Antagonistas de receptores opioides periféricos y usos de los mismos
CN101959892B (zh) * 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
US8703152B2 (en) 2008-06-03 2014-04-22 University Of Rochester Methods of treating inflammatory intestinal disease and managing symptoms thereof
WO2010002576A1 (en) 2008-07-01 2010-01-07 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
JP2010077057A (ja) * 2008-09-25 2010-04-08 Kagoshima Univ 抗食物アレルギーワクチン
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5931449B2 (ja) * 2012-01-11 2016-06-08 日東電工株式会社 医薬組成物及びその製造方法
US10940170B2 (en) 2014-07-07 2021-03-09 University Of Massachusetts Anthelmintic probiotic compositions and methods
EP3718404A1 (de) 2014-10-17 2020-10-07 Salix Pharmaceuticals, Inc. Verwendung von methylnaltrexon zur verringerung der tumorprogression
US11484568B2 (en) 2016-01-15 2022-11-01 University Of Massachusetts Anthelmintic compositions and methods
US11844815B2 (en) 2017-05-23 2023-12-19 University Of Massachusetts Purified anthelmintic compositions and related methods
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020257017A1 (en) 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE621398A (de) * 1900-01-01
US3143473A (en) * 1961-08-16 1964-08-04 Behringwerke Ag Stable, solid, oral live antipoliomyelitis vaccine compositions and process for preparing them
US3458621A (en) * 1966-08-31 1969-07-29 American Home Prod Tablet dosage-form for the immunization of the intestinal tract with live virus preparations
US3909444A (en) * 1971-08-05 1975-09-30 Ncr Co Microcapsule
US3823228A (en) * 1971-09-29 1974-07-09 Univ Illinois Tge virus vaccine
US3860490A (en) * 1972-02-11 1975-01-14 Nat Patent Dev Corp Process of subjecting a microorganism susceptible material to a microorganism
US3767790A (en) * 1972-02-11 1973-10-23 Nat Patent Dev Corp Microorganisms
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US4269764A (en) * 1979-08-02 1981-05-26 Roy Patterson Preparation for treatment of allergic patients sensitive to ragweed pollen
US4469677A (en) * 1980-02-19 1984-09-04 Michael J Gabriel Polypeptide active immunosuppressant fraction
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
JPS56142211A (en) * 1980-04-09 1981-11-06 Riken Vitamin Co Ltd Production of enteric preparation
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
SE8303401D0 (sv) * 1983-06-15 1983-06-15 Pharmacia Ab Beredning och dess anvendning
GB8321178D0 (en) * 1983-08-05 1983-09-07 Beecham Group Plc Compositions
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4794000A (en) * 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
DE3431861A1 (de) * 1984-08-30 1986-03-13 Troponwerke GmbH & Co KG, 5000 Köln Pellet-zubereitung
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
EP0192321A3 (de) * 1985-01-19 1987-09-02 Beecham Group Plc Allergene enthaltende Arzneimittel mit magensaftresistentem Überzug
CH663900A5 (de) * 1985-05-06 1988-01-29 Cernitin Sa Pharmazeutisches praeparat zur prophylaktischen behandlung von allergien und verfahren zur herstellung dieses praeparates.
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US4820627A (en) * 1986-03-24 1989-04-11 Em Diagnostic Systems, Inc. Method of preparing particles suitable for tabletting into diagnostic reagents
JPH0759496B2 (ja) * 1986-03-25 1995-06-28 ロ−ト製薬株式会社 歯周病治療剤
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2609895B1 (fr) * 1987-01-28 1991-06-28 Bruttmann Georges Nouvelles formes galeniques d'allergenes pour administration par voie per- et sub-linguale
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPS6417A (en) * 1987-02-20 1989-01-05 Shikoku Chem Corp Chemotherapeutic agent composition
US4874613A (en) * 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5116612A (en) * 1987-06-23 1992-05-26 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5049390A (en) * 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5236713A (en) * 1987-10-21 1993-08-17 Teikoku Seiyaku Kabushiki Kaisha Preparation for intermittently releasing active agent applicable to oral cavity
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
WO1990011070A1 (en) * 1989-03-17 1990-10-04 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5047258A (en) * 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
AU7908791A (en) * 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
JP2635444B2 (ja) * 1990-10-15 1997-07-30 オートイミューン インク 自己抗体の経口投与による自己免疫性疾患の治療
JPH04230625A (ja) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
ES2109362T3 (es) † 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release

Also Published As

Publication number Publication date
US5591433A (en) 1997-01-07
DK0603992T3 (da) 1997-03-24
NZ245618A (en) 1994-10-26
GR3035452T3 (en) 2001-05-31
AU3104593A (en) 1994-07-07
ATE143803T1 (de) 1996-10-15
EP0603992B2 (de) 2000-12-06
EP0603992B1 (de) 1996-10-09
CA2086631A1 (en) 1994-06-23
ES2095001T3 (es) 1997-02-01
AU664222B2 (en) 1995-11-09
SG52402A1 (en) 1998-09-28
JPH0710771A (ja) 1995-01-13
EP0603992A1 (de) 1994-06-29
CA2086631C (en) 1998-10-06
ES2095001T5 (es) 2001-03-16
GR3022090T3 (en) 1997-03-31
DE69305313T3 (de) 2001-06-21
DE69305313T2 (de) 1997-02-20
DK0603992T4 (da) 2001-03-05

Similar Documents

Publication Publication Date Title
ATE143803T1 (de) Orale verabreichung von immunologischen aktiven biomolekülen und anderen therapeutischen proteinen
ATE158180T1 (de) Oral verabreichbare therapeutische proteine und herstellungsverfahren
RU93004764A (ru) Амиды сульфамидо- и сульфамидокарбонилпиридин-2-карбоновых кислот, их пиридин-n-оксиды, способ их получения и их применение в качестве лекарственных препаратов
NO964864L (no) Orale, flytende alendronatpreparater
ATE298561T1 (de) Orale dareichungsform
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
SE8505569D0 (sv) Enteralt preparat
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
RU1808324C (ru) Способ профилактики и лечени казеинобезоарной болезни новорожденных гн т
DE2640707C3 (de) Verfahren zur Herstellung von Arzneipräparaten mit einem Gehalt an von im Darm resorbierbaren Protein und Peptidlösungen
RU94028204A (ru) Препарат "уберсан" для лечения мастита у сельскохозяйственных животных
RU94019564A (ru) Способ лечения желудочно-кишечных заболеваний
RU2099061C1 (ru) Способ лечения нейродермита
RU93056259A (ru) Средство для лечения диспепсии телят
RU93009804A (ru) Вакцина против эшерихиоза животных
RU2000104571A (ru) Способ коррекции иммунной недостаточности при желудочно-кишечных заболеваниях поросят
RU94016574A (ru) Препарат для лечения и профилактики мастита крупного рогатого скота в сухостойный период
RU95105357A (ru) Способ лечения пищевой аллергии
RU94016573A (ru) Препарат для лечения и профилактики мастита крупного рогатого скота в сухостойный период
RU2001113054A (ru) Способ лечения послеродового острого гнойно-катарального эндометрита коров
RU2002108764A (ru) Способ лечения заболеваний желудочно-кишечного тракта телят
RU2000126015A (ru) Лекарственное средство для лечения и профилактики болезней, вызываемых недостаточностью селена в организме сельскохозяйственных животных
RU98119939A (ru) Лекарственное средство и способ стимуляции иммунитета у больных острыми воспалительными заболеваниями придатков матки
RU93056258A (ru) Способ лечения диспепсии телят
SE9003096D0 (sv) Device for administering a physiologically active substance to the gastro-intestinal tract

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
R071 Expiry of right

Ref document number: 603992

Country of ref document: EP